Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies
Arrigo F.G. Cicero, Roberto Pontremoli, Federica Fogacci, et al.
Drug Safety (2020) Vol. 43, Iss. 8, pp. 727-736
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
Harold Bays, Maciej Banach, Alberico L. Catapano, et al.
Journal of clinical lipidology (2020) Vol. 14, Iss. 5, pp. 649-659.e6
Open Access | Times Cited: 88
New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?
Dan Atar, J. Wouter Jukema, Bart Molemans, et al.
Atherosclerosis (2021) Vol. 319, pp. 51-61
Open Access | Times Cited: 66
Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome
Gianni Biolo, Pierandrea Vinci, Alessandro Mangogna, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 41
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Emanuel Raschi, Manuela Casula, Arrigo F.G. Cicero, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108507-108507
Open Access | Times Cited: 34
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Saverio Muscoli, Mihaela Ifrim, Massimo Russo, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 16, pp. 4716-4716
Open Access | Times Cited: 26
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout
Zihan Hou, Aijinxiu Ma, Jiale Mao, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 12, pp. 895-909
Closed Access | Times Cited: 16
Associations between lipid-lowering drugs and urate and gout outcomes: a Mendelian randomization study
Min Liu, Na Yin, Yuhang Zhu, et al.
Frontiers in Endocrinology (2025) Vol. 15
Open Access
Novel insights into post-marketing AEs associated with bempedoic acid: A comprehensive analysis utilizing the FAERS database
Xinzhe Wang, Yang Liu, Huawei Han, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
The effect of highly bioavailable forms of curcumin on lipoprotein(a) plasma levels: a systematic review and meta-analysis of randomized clinical studies
Federica Fogacci, Ashot Avagimyan, Arturo Cesaro, et al.
Prostaglandins & Other Lipid Mediators (2025) Vol. 178, pp. 106994-106994
Open Access
New and emerging lipid-modifying drugs to lower LDL cholesterol
Constantine E. Kosmas, Dafni Pantou, Andreas Sourlas, et al.
Drugs in Context (2021) Vol. 10, pp. 1-22
Open Access | Times Cited: 26
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Chih‐Kuo Lee, Che‐Wei Liao, Shih‐Wei Meng, et al.
Biomedicines (2021) Vol. 9, Iss. 8, pp. 985-985
Open Access | Times Cited: 24
Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia
Arrigo F.G. Cicero, Federica Fogacci, Raffaele Ivan Cincione
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 9, pp. 1031-1038
Closed Access | Times Cited: 19
Current and future options in cholesterol lowering treatments
Avishay Elis
European Journal of Internal Medicine (2023) Vol. 112, pp. 1-5
Open Access | Times Cited: 7
Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper
Furio Colivicchi, Stefania Angela Di Fusco, Pietro Scicchitano, et al.
Journal of Cardiovascular Medicine (2020) Vol. 22, Iss. 3, pp. 162-171
Closed Access | Times Cited: 15
Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance
Andrey V. Susekov, L. A. Korol, Gerald F. Watts
Cardiovascular Drugs and Therapy (2021) Vol. 35, Iss. 4, pp. 841-852
Closed Access | Times Cited: 12
Untangling the relationship between bempedoic acid and gout: results from a systematic literature review
Alessia Alunno, Francesco Carubbi, Elena Campanozzi, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 4
Lipoprotein dysfunction in patients with chronic kidney disease (CKD). Pathogenesis and treatment of CKD dyslipidemia (literature review)
В. М. Ермоленко
Nephrology (Saint-Petersburg) (2024) Vol. 28, Iss. 1, pp. 13-29
Closed Access | Times Cited: 1
Impact of anti-oestrogen therapy on lipoprotein(a) in postmenopausal women: a systematic review and meta-analysis of double-blind placebo-controlled clinical studies
Federica Fogacci, Claudio Borghi, Sergio Davinelli, et al.
Endocrine (2022) Vol. 80, Iss. 2, pp. 292-302
Closed Access | Times Cited: 7
Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis
Walter Masson, Martín Lobo, Augusto Lavalle Cobo, et al.
Clínica e Investigación en Arteriosclerosis (2020)
Closed Access | Times Cited: 10
Bempedoic acid: A nonstatin drug for the management of hypercholesterolemia
Asvitha Govindaraju, Sarvesh Sabarathinam
Health Science Reports (2021) Vol. 4, Iss. 4
Open Access | Times Cited: 9
Role of Bempedoic Acid in Dyslipidemia Management
Michael S. Kelly, Elisabeth M. Sulaica, Craig J. Beavers
Journal of Cardiovascular Pharmacology (2020) Vol. 76, Iss. 4, pp. 376-388
Closed Access | Times Cited: 9
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology
Giuseppe Patti, Ilaria Cavallari, Arturo Cesaro, et al.
Vascular Pharmacology (2022) Vol. 148, pp. 107137-107137
Closed Access | Times Cited: 6
Bempedoic Acid and Statins in Lipid-Lowering Strategy: Which Came First, the Egg or the Chicken?
Francesco Natale, Riccardo Molinari, Rosa Franzese, et al.
Future Pharmacology (2023) Vol. 3, Iss. 2, pp. 392-406
Open Access | Times Cited: 3
Efficacy and safety of bempedoic acid lipid-lowering therapy: a systematic review and meta-analysis of randomized controlled trials
Shravan Venkatraman, Saibal Das, Madhavi Eerike, et al.
European Journal of Clinical Pharmacology (2023) Vol. 79, Iss. 11, pp. 1453-1463
Closed Access | Times Cited: 3
Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy
Brian Tomlinson, Paul Chan, Yuzhen Zhang, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 17, pp. 2137-2151
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top